Stay updated on CD19/22 CAR T Cells in DLBCL Clinical Trial
Sign up to get notified when there's something new on the CD19/22 CAR T Cells in DLBCL Clinical Trial page.

Latest updates to the CD19/22 CAR T Cells in DLBCL Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov site revision identifier changes from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check8 days agoChange DetectedThe ClinicalTrials.gov record for the AUTO3 study in relapsed or refractory diffuse large B-cell lymphoma is displayed, including its terminated status, study details, eligibility criteria, outcomes, and results.SummaryDifference65%

- Check15 days agoChange DetectedThe footer’s displayed site revision changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check29 days agoChange DetectedA sitewide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the 403 error page. The site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check43 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study page now renders a 403 Forbidden error page with a header and a Home button, replacing the detailed study information. This indicates the study record is currently inaccessible on ClinicalTrials.gov.SummaryDifference20%

Stay in the know with updates to CD19/22 CAR T Cells in DLBCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CD19/22 CAR T Cells in DLBCL Clinical Trial page.